Comparison of the Performance and Safety of T2769 Versus Hylo-Forte® in the Treatment of Moderate to Severe Dry Eye Syndrome.

Launched by LABORATOIRES THEA · Apr 16, 2024

Keywords

ClinConnect Summary

This clinical trial is comparing two treatments for moderate to severe dry eye syndrome: T2769 and Hylo-Forte®. The goal is to see if T2769 works just as well as Hylo-Forte® in improving eye symptoms after 36 days of treatment. This is important because many people with dry eyes struggle to find effective relief, even when using artificial tears.

To be eligible for this trial, participants need to be at least 18 years old and must have experienced dry eye symptoms for at least a month, despite using artificial tears. People with certain vision problems or other eye conditions won’t be able to participate. While the trial is not yet recruiting, those who take part can expect to have their eye symptoms evaluated to see how well the treatments work. This study is designed to help improve treatment options for dry eye syndrome in the future.

Gender

ALL

Eligibility criteria

• Main Inclusion Criteria (At Screening visit):
• • Informed consent signed and dated (obtained prior to initiating any procedures).
• • Patient aged ≥18 years old.
• • Persistence of dry eye syndrome, despite artificial tears use in the previous month prior to the screening visit
• Main Exclusion Criteria (At both Screening and Randomisation visits):
• • Far Best-Corrected Visual Acuity (BCVA) ≥+0.7 LogMar (e.g., ≤0.2 in decimal value or ≤20/100 Snellen equivalent or ≤50 letters Early Treatment Diabetic Retinopathy Study (ETDRS)).
• • Patient with previous or current ophthalmic condition